Welcome to The Lab — start here
Welcome to The Lab — the research community behind The Vial Theory. 🧪 This is a space for evidence first discussion of peptide science. A few quick orientations: Theories are post…
Loading
Loading
The Vial Theory community is for educational and research discussion only. User content is not medical advice. Always consult a licensed healthcare professional before making health-related decisions.
Ask questions, share sources, and refine ideas with the community. Add Signal to what is useful, Challenge what needs evidence, and earn Vial Score for credible contributions. Discussion is free and open.
Welcome to The Lab — the research community behind The Vial Theory. 🧪 This is a space for evidence first discussion of peptide science. A few quick orientations: Theories are post…
New Research Brief is up: CagriSema and the Two Hormone Bet. The short version: CagriSema pairs cagrilintide (a long acting amylin analog) with semaglutide (a GLP 1) in one weekly…
Here's a clean one to argue with evidence, not vibes. Claim: adding an amylin analog (cagrilintide) on top of a GLP 1 (semaglutide) produces meaningfully more benefit than the GLP…
If you're just getting into peptides, these three questions filter out most of the hype: 1. Is it human evidence? A result in mice is a hypothesis, not proof. Compounds with only a…
Why pair two appetite hormones instead of pushing one harder? Because they don't fully overlap: GLP 1 (e.g. semaglutide) slows gastric emptying and acts on central satiety circuits…
Intro thread — tell us: What first got you reading about peptides? One compound whose evidence surprised you (in either direction). What you're hoping to learn here. I'll start: th…
Welcome to The Lab — the research community behind The Vial Theory. 🧪 This is a space for evidence first discussion of peptide science. A few quick orientations: Theories are post…
Two different strategies are worth keeping straight when you compare the metabolic peptides: Single multi receptor molecule — one engineered peptide hits several receptors. Tirzepa…
Personal reports are welcome here — they can surface questions worth studying. A few norms to keep them useful and compliant: Share observations and context , not protocols. No dos…
The single most useful filter in peptide research is regulatory status. These are not interchangeable: Approved — cleared for a specific use after large trials (e.g. semaglutide, t…
Paper: Enebo et al., The Lancet (2021) — a Phase 1b/2a trial of cagrilintide co administered with semaglutide in adults with overweight or obesity. What it tested: tolerability and…
Not every alarming anecdote is a safety signal — and "well tolerated" doesn't mean safe. How to tell the difference: Case reports (e.g. regulator warnings around the unapproved "ta…
Not every alarming anecdote is a safety signal — and "well tolerated" doesn't mean safe. How to tell the difference: Case reports (e.g. regulator warnings around the unapproved "ta…
Open peptide-research discussion that does not fit a more specific room.
1 Theory
New to peptide research? Ask foundational questions here.
1 Theory
How peptides are proposed to work — receptors, pathways, and biology.
1 Theory
Discuss safety considerations, adverse-event reports, and risk context.
1 Theory
Break down published studies, reviews, and trial data.
1 Theory
Third-party testing, purity, identity, and reference standards.
1 Theory
FDA, WADA, compounding, and global regulatory status discussion.
1 Theory
Compare and contrast peptides on evidence, mechanism, and context.
1 Theory
Share observations framed as anecdote — not medical advice.
1 Theory
Newly published research, trial readouts, and field news.
1 Theory
Structured debate where Theories are challenged and refined.
1 Theory
Official announcements from The Vial Theory team.
1 Theory